{
  "docId": "019f6b8f-1354-774d-98d0-be219b0f6eb3",
  "docSlug": "jarvis-elliott-management-gsk-letter-july-2021",
  "documentTitle": "Elliott Management GSK Letter July 2021",
  "authorId": "elliott-management-gsk-letter-july-2021",
  "authorName": null,
  "documentKindSlug": "document",
  "documentKindLabel": "Document",
  "sourceTypeSlug": "independent_analyst",
  "sourceTypeLabel": "Independent analyst",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": null,
  "aspectRatio": null,
  "pageNumber": 12,
  "pageCount": 19,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 35,
  "notes": "The slide uses a table to detail vaccine performance and includes a callout box summarizing key strategic challenges.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019f6b8f-1354-774d-98d0-be219b0f6eb3/12",
  "deckHref": "/decks/019f6b8f-1354-774d-98d0-be219b0f6eb3",
  "deckJsonHref": "/decks/019f6b8f-1354-774d-98d0-be219b0f6eb3.json",
  "deckAnchorHref": "/decks/019f6b8f-1354-774d-98d0-be219b0f6eb3#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.6,
        "x": 0.28,
        "y": 0.67
      },
      "kind": "diagram",
      "text": "mRNA focused on viral diseases; Paediatric development extremely difficult; Challenging to improve >90% efficacy",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bd2fa1ca-4c60-45bb-af20-b04154923803",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.76,
        "x": 0.118,
        "y": 0.77
      },
      "kind": "paragraph",
      "text": "Importantly, GSK also has access to novel vaccine technologies, including mRNA, through its partnerships with Curevac and Medicago, as well as its existing internal know-how in mRNA and self-amplifying RNA.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "69f913fb-16c0-4240-861a-26dcee48183b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.76,
        "x": 0.118,
        "y": 0.145
      },
      "kind": "paragraph",
      "text": "GSK is the number one player in vaccines globally, with a 15-year track record of double-digit growth, driving revenues from £1.4 billion in 2005 to £7.0 billion in 2020.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea6f001f-b765-4d67-8876-9a754148a0e2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.76,
        "x": 0.118,
        "y": 0.485
      },
      "kind": "table",
      "text": "Vaccines, Disease, Type, Populations, % 2020 Revs, Efficacy. Shingrix, Shingles, Virus, Adult, 28%, >95%. Boostrix, Infanrix, Pediarix, DTP, Bacteria, Adult + Paediatric, 16%, >95%. Menveo, Bexsero, Meningitis, Bacteria, Paediatric, 13%, >90%. Fluarix, FluLaval, Influenza, Virus, Adult, 10%, 30-60%. Rotarix, Rotavirus, Virus, Paediatric, 8%, >90%. Hepatitis franchise, Hep A, B, Virus, Adult + Paediatric, 8%, >90%. Synflorix, Pneumococcal, Bacteria, Adult + Paediatric, 6%, >90%.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "503edec7-d92a-4ea3-ae4b-511eebacea97",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.58,
        "x": 0.118,
        "y": 0.093
      },
      "kind": "title",
      "text": "A solid product portfolio underpins this growth and resilience.",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c472cb10-95c9-4916-9661-e9f215961f25",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Action Titles",
      "slug": "action-titles",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "fac49db4-3ea0-4a63-9231-6da1e5fde152",
      "evidence": "title/action-title: A solid product portfolio underpins this growth and resilience.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}